Fig. 6

LYPD1 accelerates the malignant progression of HCC. a and b Knockdown of LYPD1 with two siRNAs was validated (left in upper panel) and proliferation abilities of LYPD1-silenced Huh7 (a) and MHCC97H (b) cells were determined using CCK-8 (right in upper panel) and colony formation assays (lower panel); c and d EdU assays were performed to detect the percent of cells with active DNA replication (scale bars in c, 200 μm); Hoechst staining showed the total cells, while EdU staining represented cells in S phase. And quantification data for each group (d) was displayed on the right; e and f Migration and invasion capabilities of Huh7 (e) and MHCC97H (f) cells after LYPD1 silencing were evaluated. Representative images (scale bars, 200 μm, left panel) and quantification charts (right panel) were shown; g and h Subcutaneous tumor models were established using stable LYPD1-knockdown Huh7 (g, n = 5) and MHCC97H (h, n = 5) cells. Photographs of tumors collected from mice were shown (left panel). Then tumor weights (middle panel) and growth curves (right panel) were exhibited to compare the difference of two groups. i GEO data analysis of HCC cohorts uploaded by Roessler et al. (GSE14520) and Mas et al. (GSE14323) showed the differential expression of LYPD1 in tumor and normal tissues; j Survival analysis of HCC patients based on expression of LYPD1 was conducted using TCGA data (n = 364)